Taken together, our results suggest that evaluating the early changes in cytokines, especially IL-10 and TNF-α, would be an easily accessible tool for predicting clinical outcomes in HCC patients treated with Ate/Bev. This evidence concerns the gene IL10 and hepatocellular carcinoma.